Clinical Trial Update: A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating sutimlimab (BIVV009) for cold agglutinin disease has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cold Agglutinin Disease

Drugs mentioned

• Sutimlimab (sutimlimab)

Snippet

Sponsor: Bioverativ, a Sanofi company | Conditions: Cold Agglutinin Disease | Phase 3 | Status: COMPLETED | Results posted: 2022-12-23